產(chǎn)品詳情
簡單介紹：
Anti-SPATA5L1抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-SPATA5L1抗體用于**組化實驗,WB實驗,相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SPATA5L1
Cat. Number:
Anti-SPATA5L1抗體KL-17632R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SPATA5L1 is a 753 amino acid protein belonging to the AAA ATPase family and AFG2 subfamily. Single nucleotide polymorphisms (SNPs) present in SPATA5L1 at the glycine amidinotransferase (GATM)-SPATA5L1 locusAnti-SPATA5L1抗體 have been found to correlate with glomerular filtration rate (GFR), having significant implications for kidney disease research. SPATA5L1 localizes to cytoplasm and exists as three alternatively spliced isoforms. The gene encoding SPATA5L1 maps to human chromosome 15q21.1. Encoding more than 700 genes, chromosome 15 is made up of approximately 106 million base pairs and comprises about 3% of the human genome. Tay-Sachs disease is a lethal disorder associated with mutations of the HEXA gene, which is encoded by chromosome 15. Marfan syndrome is associated with chromosome 15 through the FBN1 gene.
Also known as:
FLJ12286; MGC5347; Anti-SPATA5L1抗體SPA5L_HUMAN; SPATA5L1; Spermatogenesis-associated protein 5-like protein 1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Rabbit, .
●
Immunogen: KLH conjugated Anti-SPATA5L1抗體synthetic peptide derived from human SPATA5L1.
●
Predicted Molecular Weight: 81kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-SPATA5L1抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
